CASTLE BIOSCIENCES, INC. (CSTL) Quick Ratio
- Quick ratio · latest quarter: Value 5.58×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 5.58× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $315.15M ÷ $56.51M ≈ 5.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 315.15M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 56.51M USD | Liabilities, Current |
| Cash and equivalents | 62.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 204.69M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 48.34M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 10.58M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $315.15M | $56.51M | $62.12M | $204.69M | $48.34M | $10.58M | 5.58× |
| 2026-03-31 | $303.95M | $48.76M | $63.76M | $197.92M | $42.26M | $10.46M | 6.23× |
| 2025-12-31 | $342.89M | $68.68M | $116.73M | $182.78M | $43.38M | $10.25M | 4.99× |
| 2025-09-30 | $337.02M | $55.31M | $85.56M | $201.99M | $49.48M | $8.65M | 6.09× |
| 2025-06-30 | $328.24M | $50.89M | $82.23M | $193.70M | $52.31M | $8.37M | 6.45× |
| 2025-03-31 | $331.50M | $37.27M | $89.69M | $185.46M | $56.35M | $6.85M | 8.89× |
| 2024-12-31 | $344.35M | $49.39M | $119.71M | $173.42M | $51.22M | $8.13M | 6.97× |
| 2024-09-30 | $330.05M | $44.30M | $94.96M | $184.83M | $50.26M | $6.57M | 7.45× |
| 2024-06-30 | $305.68M | $39.45M | $85.57M | $174.12M | $45.99M | $8.01M | 7.75× |
| 2024-03-31 | $281.91M | $31.96M | $82.95M | $156.26M | $42.70M | $7.64M | 8.82× |
| 2023-12-31 | $281.40M | $47.67M | $98.84M | $144.26M | $38.30M | $7.94M | 5.90× |
| 2023-09-30 | $266.76M | $36.32M | $91.22M | $138.53M | $37.00M | $5.77M | 7.34× |
| 2023-06-30 | $256.82M | $33.72M | $95.87M | $129.63M | $31.31M | $6.12M | 7.62× |
| 2023-03-31 | $259.78M | $30.14M | $114.82M | $117.23M | $27.73M | $4.52M | 8.62× |
| 2022-12-31 | $282.10M | $36.13M | $122.95M | $135.68M | $23.48M | $3.98M | 7.81× |
| 2022-09-30 | $288.82M | $31.94M | $134.18M | $131.80M | $22.84M | $3.80M | 9.04× |
| 2022-06-30 | (m) | $27.52M | $273.17M | (m) | $22.61M | $3.37M | (m) |
| 2022-03-31 | (m) | $39.52M | $309.02M | (m) | $19.91M | $2.35M | (m) |
| 2021-12-31 | (m) | $24.89M | $329.63M | (m) | $17.28M | $2.02M | (m) |
| 2021-09-30 | (m) | $20.99M | $363.18M | (m) | $18.53M | $2.38M | (m) |
| 2021-06-30 | (m) | $18.65M | $368.34M | (m) | $17.82M | $2.12M | (m) |
| 2021-03-31 | (m) | $17.58M | $406.98M | (m) | $14.29M | $2.31M | (m) |
| 2020-12-31 | (m) | $20.88M | $409.85M | (m) | $12.76M | $2.22M | (m) |
| 2020-09-30 | (m) | $30.24M | $183.05M | (m) | $12.62M | $1.68M | (m) |
| 2020-06-30 | (m) | $28.24M | $179.76M | (m) | $12.53M | $1.67M | (m) |
| 2020-03-31 | (m) | $15.26M | $98.65M | (m) | $14.60M | $1.22M | (m) |
| 2019-12-31 | (m) | $15.29M | $98.84M | (m) | $14.65M | $1.24M | (m) |
| 2019-09-30 | (m) | $9.24M | $94.47M | (m) | $12.37M | $821.66K | (m) |
| 2019-06-30 | (m) | $11.75M | $17.47M | (m) | $9.73M | $550.89K | (m) |
| 2018-12-31 | (m) | $6.74M | $4.48M | (m) | $12.09M | $882.23K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |